source
- Novartis and BMS pause CAR-T trials after fatal immune syndrome casesNovartis has halted several immunology and neurology studies of its CAR T candidate rapcabtagene autoleucel after three patients experienced fatal immune effector cell‑associated hemophagocytic syn…
- Roche signs $1.53 billion licensing deal with Simcere for preclinical B-cell antibodyRoche announced a licensing agreement with China's Simcere Zaiming, paying $75 million upfront and potentially up to $1.53 billion in total, for worldwide rights to a preclinical trispecific antibo…